Details

Autor(en) / Beteiligte

• Woods, Scott W
• Tully, Elizabeth M
• Walsh, Barbara C
• Hawkins, Keith A
• Callahan, Jennifer L
• Cohen, Shuki J
• Mathalon, Daniel H
• Miller, Tandy J
• McGlashan, Thomas H

Titel

Aripiprazole in the treatment of the psychosisprodrome: An open-label pilot study

Ist Teil von

• British journal of psychiatry, 2007-12, Vol.191 (S51), p.s96-s101

Ort / Verlag

London: Cambridge University Press

Erscheinungsjahr

2007

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• BackgroundResearch studies for the treatment of the putative prodromal phase ofpsychotic disorders have begun to appearAimsTo obtain preliminary evidence of the short-term efficacy and safety ofaripiprazole treatment in people with the psychosis prodromeMethodFifteen participants meeting prodrome criteria (mean age 17.1 years,s.d.=5.5) enrolled in an open-label, single-site trial withfixed-flexible dosing of aripiprazole (5–30 mg/day) for 8 weeksResultsIn the mixed-effects repeated-measures analysis, improvement frombaseline on the Scale of Prodromal Symptoms total score was statisticallysignificant by the first week. No participant converted to psychosis and13 completed treatment. Neuropsychological measures showed no consistentimprovement; mean weight gain was 1.2 kg. Akathisia emerged in 8participants, but the mean Barnes Akathisia Scale score fell to baselinelevels by the final visit. Adverse events were otherwise minimalConclusionsAripiprazole shows a promising efficacy and safety profile for thepsychosis prodrome. Placebo-controlled studies are indicated